Could sigma receptor ligands be a treatment for methamphetamine addiction?

Current Drug Abuse Reviews

Volumn 3, Issue 3, 2010, Pages 156-162

  Rodvelt, Kelli R ^a   Miller, Dennis K ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Drug discrimination; Locomotor activity; Methamphetamine; Sensitization; Sigma receptors

Indexed keywords

AC 927; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; BD 104; BD 1063; CUTAMESINE; METHAMPHETAMINE; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; N ALLYLNORMETAZOCINE; PB 28; PENTAZOCINE; PRECLAMOL; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT; LIGAND;

ARTICLE; BINDING AFFINITY; BRAIN REGION; DOPAMINE RELEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; METHAMPHETAMINE DEPENDENCE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; TREATMENT RESPONSE; VENTRAL TEGMENTUM; ANIMAL; DRUG ABUSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; REVIEW; TOXICITY AND INTOXICATION;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; LIGANDS; METHAMPHETAMINE; MOTOR ACTIVITY; NEUROTOXICITY SYNDROMES; RECEPTORS, SIGMA;

EID: 79953789746     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711003030156     Document Type: Article

References (62)

1. SAMHSA. Results from the 2007 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Rockville, MD. Substance Abuse and Mental Health Services 2008.
2. NIDA. Methamphetamine Abuse and Addiction. (NIH Publication Number 06-4210). National Institute on Drug Abuse 2006.
3. Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J. Pharmacotherapy of methamphetamine addiction: an update. Subst Abus 2008; 29: 31-49.
4. McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 2008; 35: 334-42.
5. Barr AM, Panenka WJ, MacEwan GW, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006; 31: 301-13.
6. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008; 96: 222-32.
7. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005; 75: 406-33.
8. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 1999; 289: 877-85.
9. +-dependent mechanism. J Biol Chem 2003; 278: 12070-7.
10. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 1995; 15: 4102-8.
11. Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 2001; 296: 762-7.
12. Peter D, Jimenez J, Liu Y, Kim J, Edwards RH. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J Biol Chem 1994; 269: 7231-7.
13. Mantle TJ, Tipton KF, Garrett NJ. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 1976; 25: 2073-7.
14. Mandell AJ, Morgan M. Amphetamine induced increase in tyrosine hydroxylase activity. Nature 1970; 227: 75-6.
15. Saunders C, Ferrer JV, Shi L, et al. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 2000; 97: 6850-5.
16. Nguyen EC, McCracken KA, Liu Y, Pouw B, Matsumoto RR. Involvement of sigma () receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacol 2005; 49: 638-45.
17. Stefanski R, Justinova Z, Hayashi T, Takebayashi M, Goldberg SR, Su TP. Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls. Psychopharmacology (Berl) 2004; 175: 68-75.
18. Hayashi T, Justinova Z, Hayashi E, et al. Regulation of -1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats. J Pharmacol Exp Ther 2010; 332: 1054-63.
19. Matsumoto RR, Liu Y, Lerner M, Howard EW, Brackett DJ. Sigma receptors: potential medications development target for anticocaine agents. Eur J Pharmacol 2003; 469: 1-12.
20. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-32.
21. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. Sigma receptors: biology and function. Pharmacol Rev 1990; 42: 355-402.
22. Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)- benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 1990; 527: 244-53.
23. Hanner M, Moebius FF, Flandorfer A, et al. Purification, molecular cloning, and expression of the mammalian 1-binding site. Proc Natl Acad Sci USA 1996; 93: 8072-7.
24. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009; 323: 934-7.
25. 3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc Natl Acad Sci USA 1995; 92: 3774-8.
26. Waterhouse RN, Chang RC, Atuehene N, Collier TL. In vitro and in vivo binding of neuroactive steroids to the sigma-1 receptor as measured with the positron emission tomography radioligand [18F]FPS. Synapse 2007; 61: 540-6.
27. Hayashi T, Su TP. Regulating ankyrin dynamics: Roles of sigma-1 receptors. Proc Natl Acad Sci USA 2001; 98: 491-6.
28. Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003; 10: 2073-80.
29. Su TP, Hayashi T, Vaupel DB. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the 1 receptor. Sci Signal 2009; 2: 12.
30. Patrick SL, Walker JM, Perkel JM, Lockwood M, Patrick RL. Increases in rat striatal extracellular dopamine and vacuous chewing produced by two receptor ligands. Eur J Pharmacol 1993; 231: 243-9.
31. Booth RG, Baldessarini RJ. (+)-6,7-benzomorphan sigma ligands stimulate dopamine synthesis in rat corpus striatum tissue. Brain Res 1991; 557: 349-52.
32. 3H]dopamine release from rat striatal slices by sigma receptor ligands. J Pharmacol Exp Ther 1994; 271: 212-9.
33. Minabe Y, Matsuno K, Ashby CR, Jr. Acute and chronic administration of the selective 1 receptor agonist SA4503 significantly alters the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study. Synapse 1999; 33: 129-40.
34. Meurs A, Clinckers R, Ebinger G, Michotte Y, Smolders I. Sigma 1 receptor-mediated increase in hippocampal extracellular dopamine contributes to the mechanism of the anticonvulsant action of neuropeptide Y. Eur J Neurosci 2007; 26: 3079-92.
35. Yamazaki Y, Ishioka M, Matsubayashi H, Amano T, Sasa M. Inhibition by sigma receptor ligand, MS-377, of N-methyl- D- aspartate-induced currents in dopamine neurons of the rat ventral tegmental area. Psychopharmacology (Berl) 2002; 161: 64-9.
36. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988; 242: 715-23.
37. Felder CC, Jose PA, Axelrod J. The dopamine-1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylate cyclase. J Pharmacol Exp Ther 1989; 248: 171-5.
38. Friedman E, Jin LQ, Cai GP, et al. D1-like dopaminergic activation of phosphoinositide hydrolysis is independent of D1A dopamine receptors: evidence from D1A knockout mice. Mol Pharmacol 1997; 51: 6-11.
39. Wang HY, Undie AS, Friedman E. Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation. Mol Pharmacol 1995; 48: 988-94.
40. Hiranita T, Soto PL, Tanda G, Katz JL. Reinforcing effects of - receptor agonists in rats trained to self-administer cocaine. J Pharmacol Exp Ther 2010; 332: 515-24.
41. Skuza G. Effect of sigma ligands on the cocaine-induced convulsions in mice. Pol J Pharmacol 1999; 51: 477-83.
42. Ukai M, Mori E, Kameyama T. Modulatory effects of morphine, U-50488H and 1,3-di-(2-tolyl)guanidine on cocaine-like discriminative stimulus in the rat using two-choice discrete-trial avoidance paradigm. Methods Find Exp Clin Pharmacol 1997; 19: 541-6.
43. Bowen WD, De Costa B, Hellewell SB, Walker JM, Rice KC. [3H]-(+)-Pentazocine: a potent and highly selective benzomorphans-based probe for sigma-1 receptors. Mol Neuropharmacol 1993; 3: 117-126.
44. Berardi F, Abate C, Ferorelli S, Colabufo NA, Perrone R. 1- Cyclohexylpiperazine and 3,3-dimethylpiperidine derivatives as sigma-1 (sigma1) and sigma-2 (sigma2) receptor ligands: a review. Cent Nerv Syst Agents Med Chem 2009; 9: 205-19.
45. Rao TS, Mick SJ, Cler JA, et al. Effects of sigma ligands on mouse cerebellar cyclic guanosine monophosphate (cGMP) levels in vivo: further evidence for a functional modulation of N-methyl-Daspartate (NMDA) receptor complex-mediated events by sigma ligands. Brain Res 1991; 561: 43-50.
46. Ujike H, Okumura K, Zushi Y, Akiyama K, Otsuki S. Persistent supersensitivity of sigma receptors develops during repeated methamphetamine treatment. Eur J Pharmacol 1992; 211: 323-8.
47. Kitanaka J, Kitanaka N, Tatsuta T, et al. Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice. Psychopharmacology (Berl) 2009; 203: 781-92.
48. Lever JR, Gustafson JL, Xu R, Allmon RL, Lever SZ. 1 and 2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse 2006; 59: 350-8.
49. Fujiwara S, Kuribara H, Tadokoro S. Effects of repeated administration of pentazocine on ambulatory activity in mice: comparison with the effects of morphine and methamphetamine. Jpn J Pharmacol 1990; 54: 61-7.
50. Bhosale BB, Balsara JJ, Jadhav JH. Effects of pentazocine on dopamine-dependent behaviours in mice. Indian J Exp Biol 1997; 35: 448-50.
51. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. Binding properties of SA4503, a novel and selective 1 receptor agonist. Eur J Pharmacol 1996; 306: 271-9.
52. Rodvelt KR, Oelrichs CE, Blount LR, et al. The sigma receptor agonist both attenuates and enhances the effects of methamphetamine. Manuscript under review.
53. Katz JL, Libby TA, Kopajtic T, Husbands SM, Newman AH. Behavioral effects of rimcazole analogues alone and in combination with cocaine. Eur J Pharmacol 2003; 468: 109-19.
54. Ujike H, Kuroda S, Otsuki S. sigma Receptor antagonists block the development of sensitization to cocaine. Eur J Pharmacol 1996; 296: 123-8.
55. Martin-Fardon R, Maurice T, Aujla H, Bowen WD, Weiss F. Differential effects of sigma1 receptor blockade on selfadministration and conditioned reinstatement motivated by cocaine vs natural reward. Neuropsychopharmacol 2007; 32: 1967-73.
56. Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 2001; 36: 1-22.
57. Weigl M, Bedurftig S, Maier CA, Wunsch B. Conformationally constrained ethylenediamines: synthesis and receptor binding of 6,8-diazabicyclo[3.2.2]nonanes. Bioorg Med Chem 2002; 10: 2245-57.
58. Terleckyj I, Sonsalla PK. The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors. J Pharmacol Exp Ther 1994; 269: 44-50.
59. Matsumoto RR, Shaikh J, Wilson LL, Vedam S, Coop A. Attenuation of methamphetamine-induced effects through the antagonism of sigma () receptors: Evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol 2008; 18: 871-81.
60. Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, De Costa BR. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 1995; 280: 301-10.
61. Ujike H, Kanzaki A, Okumura K, Akiyama K, Otsuki S. Sigma () antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci 1992; 50: PL129-34.
62. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993; 18: 247-91.